Drug Profile


Alternative Names: IMC-11F8; LY 3012211; Portrazza

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImClone Systems
  • Developer Eli Lilly
  • Class Antineoplastics; Fab fragments; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Solid tumours
  • No development reported Colorectal cancer

Most Recent Events

  • 07 Dec 2016 Adverse events data from a phase II trial in Non-small cell lung cancer presented at the 41st European Society for Medical Oncology Congress
  • 01 Dec 2016 Eli Lilly and AstraZeneca initiate a phase-I clinical trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in France, ans Spain (IV) (NCT02789345)
  • 21 Nov 2016 Eli Lilly withdraws a phase II trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) prior to enrolment in USA, United Kingdom, Belgium, Germany, Italy, Romania and Russia (IV) (NCT02941601)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top